Trademark: 79351356
Word
K
Status Date
Tuesday, January 2, 2024
Registration Number
7256771
Registration Date
Tuesday, January 2, 2024
Filing Date
Wednesday, July 20, 2022
Published for Opposition
Tuesday, October 17, 2023
5 Pharmaceutical preparations for the treatment of ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of diabetic macular edema; pharmaceutical preparations for the treatment of angioedema; pharmaceutical preparations for the treatment of hereditary angioedema; pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders
44 Medical and healthcare services relating to ophthalmic diseases and disorders; medical and health care services relating to diabetic macular edema; medical and healthcare services relating to angioedema; medical and healthcare services relating to hereditary angioedema; medical and healthcare services relating to diseases and disorders mediated by the contact activation system; medical and healthcare services relating to plasma kallikrein or factor XIIa mediated diseases or disorders
10 Medical and surgical instruments and apparatus for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders; drug delivery devices for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders
42 Drug discovery services relating to ophthalmic diseases and disorders; drug discovery services relating to diabetic macular edema; drug discovery services relating to angioedema; drug discovery services relating to hereditary angioedema; drug discovery services relating to diseases and disorders mediated by the contact activation system; drug discovery services relating to plasma kallikrein or factor XIIa mediated diseases or disorders
The mark consists of a stylized letter K with the bottom diagonal leg of the letter K annexed at a right angle with another leg of the same length extending up and out towards the right and a small circle positioned to the right center of the letter K.
Apr 2, 2024
Final Disposition Notice Created, To Be Sent To Ib
Jan 2, 2024
Notice Of Registration Confirmation Emailed
Jan 2, 2024
Registered-Principal Register
Oct 17, 2023
Notification Processed By Ib
Oct 17, 2023
Official Gazette Publication Confirmation E-Mailed
Oct 17, 2023
Published For Opposition
Sep 27, 2023
Notification Of Possible Opposition Sent To Ib
Sep 27, 2023
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Sep 27, 2023
Notification Of Notice Of Publication E-Mailed
Sep 13, 2023
Approved For Pub - Principal Register
Sep 13, 2023
Teas/Email Correspondence Entered
Sep 13, 2023
Correspondence Received In Law Office
Sep 13, 2023
Teas Response To Office Action Received
Sep 7, 2023
Teas Change Of Correspondence Received
Sep 7, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Sep 7, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Sep 7, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Sep 7, 2023
Teas Change Of Owner Address Received
Jul 10, 2023
Refusal Processed By Ib
Jun 15, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Jun 15, 2023
Refusal Processed By Mpu
May 7, 2023
Non-Final Action (Ib Refusal) Prepared For Review
May 6, 2023
Non-Final Action Written
May 5, 2023
Assigned To Examiner
Oct 4, 2022
Application Filing Receipt Mailed
Sep 30, 2022
New Application Office Supplied Data Entered
Sep 29, 2022
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
